Related Experiment Video

Updated: Jul 9, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Diabetes prevention: still no effective drugs

    Prescrire International
    |December 21, 2007
    PubMed

    Insights

    Ramipril did not prevent adverse outcomes in the DREAM trial for patients with impaired glucose tolerance. However, rosiglitazone was associated with cardiac side effects in this large patient group.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Clinical Trials

    Background:

    • Impaired glucose tolerance (IGT) is a significant risk factor for cardiovascular disease and type 2 diabetes.
    • Interventions to prevent progression and cardiovascular events in IGT patients are crucial.

    Purpose of the Study:

    • To evaluate the efficacy of ramipril in preventing adverse cardiovascular and diabetes-related events in patients with IGT.
    • To assess the safety and cardiac effects of rosiglitazone in the same patient population.

    Main Methods:

    • The DREAM trial was a large-scale, randomized, placebo-controlled study.
    • Over 5000 patients with IGT were enrolled and followed for a defined period.

    Main Results:

    • Ramipril demonstrated no significant preventive effect on the primary composite endpoint.
    • Rosiglitazone was associated with an increased incidence of cardiac adverse effects.

    Conclusions:

    • Ramipril is not effective for preventing cardiovascular or diabetes-related events in patients with IGT.
    • The use of rosiglitazone in patients with IGT carries a risk of cardiac adverse events, warranting caution.

    More Related Videos

    An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice04:36

    An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

    Published on: January 12, 2024

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are typically...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.